|
Research Overview
Dr. Altice is currently conducting research at the interface of infectious diseases and substance abuse. He is a clinical epidemiologist and intervention researcher who has created novel programs for the treatment of HIV, HCV and Tuberculosis among vulnerable populations, including injection drug users and prisoners. In addition to advancing the science of adherence through development of directly administered antiretroviral therapy for HIV+ drug users and for released prisoners, he has been at the forefront for integrating buprenorphine treatment for individuals with HIV, HCV and mental illness – including the first implementation of buprenorphine in correctional settings.
His work has been extended globally to address the issues of integration of HIV care, substance abuse treatment and management of tuberculosis.
Dr. Altice’s commitment to improving care of incarcerated individuals is reflected in his research. He has been involved as a Principal Investigator in numerous clinical studies examining issues ranging from organizing HIV care for incarcerated persons to improving health outcomes among HIV-infected individuals who are substance abusers. He is currently leading studies that bridge the correctional to the community setting, including the use of directly observed antiretroviral therapy and opiate substitution therapy such as methadone and buprenorphine.
Education
American Board of Internal Medicine, Infectious Diseases, 1992
American Board of Internal Medicine, Internal Medicine, 1989
M.D., Emory University, 1986
M.A., Universidad de Santiago de Compostela, Spain, 1982 (Spanish literature)
B.A., Texas A&M University, 1982 (biology and Spanish)
Featured Publications
1. Basu S, Smith-Rohrberg D, Bruce RD, Altice FL. Models for Integrating Buprenorphine Therapy into the Primary HIV Care Setting. Clinical Infectious Diseases. 2006 42(5):716-721
2. Smith-Rohrberg D, Altice FL. Randomized Controlled Trials of DAART for HIV+ Patients: Questions about Study Population and Analytical Approach," Clinical Infectious Diseases. 2006;43(9):1221-2.
3. Altice FL, Sullivan LS, Rohrberg-Smith D, Basu S, Stancliff S, Eldred L. The Potential Role of Buprenorphine in the Treatment of Opioid Dependence in HIV-Infected Individuals and in HIV infection prevention. Clinical Infectious Diseases (43) suppl 4: 178-83. 2006
4. Khalsa J, Vocci F, Altice FL, Fiellin D, Miller V. Buprenorphine and HIV Primary Care: New Opportunities for Integrated Treatment. Clinical Infectious Diseases (43) suppl 4:169-72. 2006
5. Smith-Rohrberg D, Mezger J, Walton M, Bruce RD, Altice FL. Impact of Enhanced Services on Virological Outcomes in a Directly Administered Antiretroviral Therapy Trial for HIV+ Drug Users. JAIDS 43 (supp 1): 48-53. Dec 2006.
6. Ravi A, Blankenship K, Altice FL. The Association between History of Violence and HIV Risk: A Cross-Sectional Study of Female Prisoners in Connecticut. Journal of Women's Health Issues (17) 1049-3867. June 2007.
7. Springer SA, Friedland GH, Doros G, Pesanti E, Altice FL. Antiretroviral Treatment Regimen Outcomes Among HIV-Infected Prisoners. HIV Clin Trials. 2007 Jul-Aug;8(4):205-12.
8. Bruce RD, Altice FL, Friedland GH. A Review of Pharmacokinetic Drug Interactions Between Drugs of Abuse and Antiretroviral Medications: Implications and Management for Clinical Practice. Expert Review of Clinical Pharmacology, 2008; 1(1):115-127.
9. Bruce, RD, Altice FL. Case Series of the Safe Use of Buprenorphine/Naloxone in Individuals with Acute Hepatitis C Infection and Abnormal Hepatic Liver Transaminases. The American Journal of Drug and Alcohol Abuse, 2007; 33(6):869-874.
10. Altice FL, Smith-Rohrberg D, Bruce RD, Springer SA, Friedland G. (2007) Superiority of Directly Administered Antiretroviral Therapy Compared to Self-Administered Therapy among HIV-Infected Drug Users Enrolled in a Six-Month Prospective, Randomized Controlled Trial. Clinical Infectious Diseases 45: 770-778.
11. Maru DS, Bruce RD, Walton M, Mezger JA, Springer SA, Shield D, Altice FL. Initiation, Adherence, and Retention in a Randomized Controlled Trial of Directly Administered Antiretroviral Therapy. AIDS Behav, 2007; 11(7):946-57.
12. Smith Rohrberg Maru D, Basu S, Altice FL. HIV Control Efforts should directly address incarceration. The Lancet ID-RR (7) Sept 2007.
13. Bruce RD, Dvoryak S, Sylla LN, Altice FL. HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine—programme description and policy implications. International Journal of Drug Policy. 2007;(18): 326-328.
14. Basu S, Bruce RD, Barry D, Altice FL. Pharmacological Pain Control For HIV-Infected Adults With A History Of Drug Dependence. Journal of Substance Abuse Treatment. JSAT (32): 399-409. 2007
15. Copenhaver MM, Bruce RD, Altice FL. Behavioral counseling content for optimizing the use of buprenorphine for opioid dependence in community-based settings: A review of the empirical evidence. American Journal of Drug and Alcohol Abuse. 2007; 33(5):643-54.
16. Smith-Rohrberg D, Kozal M, Springer SA, Bruce RD, Altice FL. Directly Administered Antiretroviral Therapy for HIV-Infected Drug Users Does Not Impact Antiretroviral Resistance: Results from a Randomized, Controlled Trial. J Acquir Immune Defic Syndr 46(5): 555-563. 2007
17. Bruce RD, Govindasamy S, Sylla LN, Haddad MS, Kamarulzaman A, Altice FL. Case Series of Buprenorphine Injectors in Kuala Lumpur, Malaysia. American Journal of Drug and Alcohol Abuse. iFirst: 1–7, 2008 ISSN: 0095-2990 print / 1097-9891 online DOI:10.1080/00952990802122259.
|
